Estrella Immunopharma Inc...
(ESLA)
undefined
undefined%
At close: undefined
1.15
-0.77%
After-hours Jan 06, 2025, 03:59 PM EST
Company Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. is based in EmeryVille, California.
Estrella Immunopharma Inc.
| Country | United States |
| IPO Date | Sep 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Dr. Cheng Liu Ph.D. |
Contact Details
Address: 5858 Horton Street EmeryVille, California United States | |
| Website | https://www.estrellabio.com |
Stock Details
| Ticker Symbol | ESLA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001844417 |
| CUSIP Number | n/a |
| ISIN Number | US2975841048 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cheng Liu Ph.D. | Chief Executive Officer, President & Director |
| Jiandong Xu | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | S-8 | Filing |
| Dec 17, 2024 | 424B3 | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 12, 2024 | S-3 | Filing |
| Dec 09, 2024 | 424B3 | Filing |
| Dec 06, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 424B3 | Filing |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 424B3 | Filing |